This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Zinc makes up about 70 ppm (0.007%) of Earth's crust in mass, making it the 24th-most abundant crustal element. It also makes up 312 ppm of the Solar System, where it is the 22nd most abundant element. Typical background concentrations of zinc do not exceed: 1 μg/m3 in atmosphere, 300 mg/kg in soil, 100 mg/kg in vegetation, 20 μg/L in freshwater, and 5 μg/L in seawater. The element is normally found in association with other base metals such as copper and lead in the form of ores. Zinc is a chalcophile, meaning the element is more likely to be found associated with sulfur and other heavy chalcogens, rather than with the light chalcogen oxygen or with non-chalcogen electronegative elements such as the halogens. Sulfides formed as the crust solidified under the highly reducing conditions of the young Earth's atmosphere. Sphalerite, a crystalline form of zinc sulfide, is the most heavily mined zinc-containing ore as it contains 60–62% zinc by mass. Other source minerals for zinc include smithsonite (zinc carbonate), hemimorphite (zinc silicate), wurtzite (another zinc sulfide), and sometimes hydrozincite (basic zinc carbonate). With the exception of wurtzite, all the other minerals were formed by weathering of the primordial zinc sulfides. Currently identified zinc resources across the globe total 1.9–2.8 billion tonnes. Large deposits are in Australia, China, Canada, and the United States, with the largest potential reserves in Iran.
This abuse of power by local leaders exacerbated the violent purges and terror campaigns carried out by Stalin against members of the party deemed to be traitors. With the Great Purge (1936–1938), Stalin rid himself of internal enemies in the party and rid the Soviet Union of any alleged socially dangerous and counterrevolutionary person who might have offered legitimate political opposition to Marxism–Leninism. Stalin allowed the secret police NKVD (People's Commissariat for Internal Affairs) to rise above the law and the GPU (State Political Directorate) to use political violence to eliminate any person who might be a threat, whether real, potential, or imagined. As an administrator, Stalin governed the Soviet Union by controlling the formulation of national policy, but he delegated implementation to subordinate functionaries. Such freedom of action allowed local communist functionaries much discretion to interpret the intent of orders from Moscow, but this allowed their corruption. To Stalin, the correction of such abuses of authority and economic corruption were responsibility of the NKVD. In the 1937–1938 period, the NKVD arrested 1.5 million people, purged from every stratum of Soviet society and every rank and file of the party, of which 681,692 people were killed as enemies of the state.
Scorpions are sometimes kept as pets, in the same way as other dangerous animals like snakes and tarantula spiders. Popular Science Monthly carried an article entitled "My pet scorpion" as early as 1899.
Sources: en.wikipedia.org
If the argument holds, then Form 2 could be marketed as generics in 1995 at the expiration of the 1978 patent. Since an additional seven years of exclusive marketing is highly profitable, Glaxo fought back. In order to win the first Glaxo, Inc. v. Novopharm, Ltd case, Glaxo argued successfully that Form 1 could be produced according to the 1978 patent procedure in a carefully quarantined environment, and that Novopharm had been producing Form 2 due to disappearing polymorphs. The organic chemist Jack Baldwin, acting as a witness to Glaxo, had two of his postdoctoral researchers, for three times, produce Form 1 according to the 1978 patent procedure. Consequently, the court ruled that the 1985 patent is valid and covers Form 2. Subsequent to losing the case, Novopharm attempted to bring Form 1 to market, so Glaxo sued them again in the second Glaxo, Inc. v. Novopharm, Ltd case. Glaxo argued that Novopharm could not market generics containing even trace amounts of Form 2. In particular, that means any generic Zantac containing an infrared spectrogram peak at 1045 cm−1 infringes their 1985 patent. However, during the prosecution of the first case, Glaxo had already accepted that the 1985 patent covered only products containing chemicals with a specific, 29-peak infrared (IR) spectrum. This was intended to avoid double patenting—Glaxo had to emphasize the unique aspects of Form 2 to distinguish it from the invention described in the 1978 patent.
However, correct DNA structure can form even when the bases are not paired via hydrogen bonding; that is, the bases pair thanks to hydrophobicity, as studies have shown with DNA isosteres (analogues with same number of atoms) such as the thymine analogue 2,4-difluorotoluene (F) or the adenine analogue 4-methylbenzimidazole (Z). An alternative hydrophobic pair could be isoquinoline and pyrrolo[2,3-b]pyridine. Other noteworthy basepairs:
== Mechanism of action == Naltrexone and its active metabolite, 6-β-naltrexol, are competitive antagonists at μ-opioid, κ-opioid, and, to a lesser extent, δ-opioid receptors. Standard therapeutic doses of naltrexone block these receptors, achieving two main effects: first, they prevent the inhibition of GABA receptors, which normally suppress neuron activity; many recreational drugs inhibit GABA, thereby increasing neuronal activation, and by blocking GABA inhibition, normal GABA activity resumes. Second, naltrexone blocks dopamine release, since many recreational drugs stimulate dopamine as part of the brain's reward system, which generates feelings of pleasure. As naltrexone is a competitive antagonist at the identical sites of action of many opioid agonists, such as morphine, care must be taken to ensure that low-dose naltrexone is not taken near the same time as these medications, as they will not be as efficacious in relieving pain.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.